ELSA
Dead · Refused DEAD/APPLICATION/Refused/Dismissed or Invalidated
What this record means
The record shows that the “ELSA” application filed by Fosun Pharma USA Inc. on April 18 2024 is now dead, having been abandoned on March 30 2026 because no Statement of Use or extension was filed after the Notice of Allowance was issued. The goods and services listed are limited to Class 005 pharmaceuticals—specifically preparations for treating central nervous system, neuromuscular, metabolic and RNA‑related diseases—and Class 042 scientific and technology services, including bioinformatics‑based anti‑sense oligonucleotide research, gene‑therapy research and pharmaceutical drug‑development services. A similar name used in these pharmaceutical or biotech research contexts would create the closest record‑based concern, while uses outside those fields are farther from the scope shown. The prosecution history shows a final refusal, a subsequent allowance, and then abandonment for lack of use, but the mark never reached registration on the Supplemental Register. The latest meaningful event is the abandonment notice on March 30 2026, and the supplied history shows no oppositions, cancellations or court actions. I'd treat this as a meaningful concern if you plan a name in the same drug‑development or biotech research space.
Informational only - not legal advice.Mark Trademark, Service Mark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Intent-to-Use (§1(b)). |
| Status | Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page. |
Key dates
| Application filed | Apr 18, 2024 |
| Published for opposition | Jul 01, 2025 |
| Notice of Allowance | Aug 26, 2025 |
| Status date | Mar 30, 2026 |
Goods & services
Pharmaceutical preparations for the treatment of central nervous system diseases, neuromuscular diseases, metabolic diseases, and diseases related to RNA processing and translation
Biochemical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Biotechnology research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Gene therapy research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Pharmaceutical drug development services, namely, development and design of anti-sense oligonucleotides; Pharmaceutical products development, namely, development and design of anti-sense oligonucleotides; Pharmaceutical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of RNA-targeted drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of gene therapy, namely, using bioinformatics to develop knowledge of the RNA transcript splicing regulation machinery to improve efficacy; Research and development in the pharmaceutical and biotechnology fields, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, development and design of anti-sense oligonucleotides; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy, namely, development and design of anti-sense oligonucleotides
Owner & representation
| Owner | Fosun Pharma USA Inc. |
| Address | 104 Carnegie Center Drive, Suite 204, Princeton, NEW JERSEY UNITED STATES 08540 |
| Entity | CORPORATION - organized in DELAWARE |
| Attorney of record | Perry Gattegno |
| Correspondent | Perry Gattegno |
| Attorney email | p********@*****.com |
| Correspondent email | 2 emails |
| Correspondent phone | 3********5 |
| Correspondent address | Chicago, ILLINOIS |